The plan lowers the evidence bar at launch and moves the proof to later real-world data, where insurers doubt it exists.
The plan lowers the evidence bar at launch and moves the proof to later real-world data, where insurers doubt it exists.
Pricing & Reimbursement
AbbVie’s Juvmo Won FDA Approval Three Days Before ICER Holds a Public Meeting on Its Value
AbbVie now has to name a price for Juvmo into a benchmark that ICER set before the drug was even approved.
Sleeve Gastrectomy Beat GLP-1s on Two-Year Cost by $12,794 in a Study Intuitive Surgical Funded
The cost gap rests on drug prices that have already moved, in a study whose funder sells surgical systems.
AbbVie Largely Dropped Its Constitutional Case but Still Says Botox Is Plasma-Derived and Exempt
Constitutional challenges to Medicare negotiation have failed repeatedly. AbbVie is now betting on the definition of its product.
Medicare’s Preliminary Lab Rates Cut Genomic Sequencing 23% and Proprietary Tests Just 2.4%
The average cut is 16%. The tests carrying the newest science take the deepest cuts, and proprietary ones barely move.
India Got Three Different Access Mechanisms in Four Days
Three routes to patients in four days. In a market that pays out of pocket, not one announcement carries a price.
Japan Clears Five Products in a Day, Two With a Price Cut Attached
Five approvals, one calendar date, one November pricing round. The two expansions are the ones the system taxes.
GENEROUS Signings Jump From Seven to 40 States in a Week
Forty states signed. Reporting last week put it at seven. The list CMS has never published is the manufacturers.
Korea Repriced 36 Fewer Items This Year and Took Out the Same ₩33.9 Billion
Thirty-six fewer items produced the same saving. Nothing about efficacy changed. The medicines that grew paid for it.
GENEROUS Lets Manufacturers Cut Medicaid Prices Without Touching Best Price or 340B
Seven of 19 applicant states have signed. CMS itself tells them to check whether its international price beats the rebates they already have.